MOTS-c: A Mitochondrial Peptide With Real Biology and Modest Human Data

MOTS-c is a 16-amino-acid peptide encoded within mitochondrial DNA. That detail is unusual: most peptides come from nuclear genes. MOTS-c was identified as part of a class of mitochondrial-derived peptides that appear to act as signals between mitochondria and the rest of the cell, particularly around energy metabolism and stress response.

What it does

In preclinical studies, MOTS-c influences AMPK activation, glucose uptake, and has been described as an "exercise mimetic" in mouse models, improving running capacity and metabolic parameters. Human data exists but is limited, and most of it is observational (lower circulating MOTS-c in older or insulin-resistant individuals) rather than from controlled trials.

Typical protocol shape

Self-experimenters typically use:

• Subcutaneous injection
• A cycle of weeks on, weeks off
• Sometimes timed around training blocks rather than continuous
• Often paired with broader metabolic tracking

There is no established therapeutic dose in humans for the use cases people pursue. Do not extrapolate from mouse mg/kg dosing.

What to track daily

• Dose and injection site
• Fasting glucose if you have a glucometer or CGM
• Resting heart rate
• Subjective energy on a 1 to 10 scale
• Sleep duration and quality

What to track weekly

• Body weight
• Body composition if you have a reliable method
• Exercise performance, particularly aerobic capacity proxies (resting HR, HRV, perceived exertion at fixed workloads)
• Recovery between sessions

Bloodwork worth doing

• Fasting glucose and insulin
• HbA1c
• Lipid panel
• Comprehensive metabolic panel
• Inflammatory markers (hsCRP) if you have a baseline

Realistic expectations

The compelling MOTS-c story is largely preclinical. Human users sometimes report better aerobic capacity and easier glycemic control, but well-controlled trials at the doses people use are not available. Set measurable targets before starting and a stop date if you do not see them.

Common mistakes

• Treating animal data as if it translates 1:1
• Stacking with other metabolic compounds, making attribution impossible
• Skipping baseline labs
• Not tracking exercise performance, which is the most likely place to see an effect
• Continuing indefinitely without checking whether anything changed

A tracking template

In Peptid AI, log each injection with site and dose, then track morning fasting glucose, resting HR, and HRV. Add a weekly performance metric: a fixed cardio test, a strength benchmark, or perceived exertion at a standard workload. Compare months on and off.

Bottom line

MOTS-c is one of the most biologically interesting peptides in the metabolic space, and one of the most over-extrapolated. The honest stance is curious, cautious, and measurement-driven.

A note on legal status: MOTS-c is part of the FDA's 2026 peptide-compounding review. It sits alongside BPC-157, TB-500, and KPV on the agenda for the Pharmacy Compounding Advisory Committee meeting on July 23-24, 2026, which follows the April 2026 removal of BPC-157 from the 503A Category 2 list. Expect compounding availability and legal framing to shift through the year.

Peptid AI is an educational and self-tracking tool. Nothing in this post is medical advice. Doses mentioned reflect what is commonly reported in research literature — they are not recommendations. Always consult a qualified physician before starting, changing, or stopping any protocol.